Halozyme Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Halozyme Therapeutics

06/08/2026 22:37

Halozyme Therapeutics, Inc. HALO.OQ reported quarterly adjusted earnings of $2.28​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $1.54.  The mean expectation of eight analysts for the quarter was for earnings of $1.84 per share. Wall Street expected results to range from $1.73  to $1.90 per share.
Revenue fell 60.2% to $129.63 million from a year ago; analysts expected $407.49 million. 
Halozyme Therapeutics, Inc.'s reported EPS for the quarter was $1.90​.
The company reported quarterly net income of $229.91 million.
Halozyme Therapeutics, Inc. shares had risen by 6.8% this quarter and gained 24.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 1% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Halozyme Therapeutics, Inc. is $91.23, about 8.4% above its last closing price of $83.59
This summary was machine generated from LSEG data August 6 at 09:37 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
1.84
2.28
Beat
Mar. 31 2026 
1.53
1.60
Beat
Dec. 31 2025 
2.20
-0.24
Missed
Sep. 30 2025 
1.63
1.72
Beat